IDRINOL SOLUTION AMPOULES OF 0.1/ML 5 ML

$18.90
No tax

IDRINOL SOLUTION AMPOULES OF 0.1/ML 5 ML - 10 pcs

Quantity

 

Security policy (edit with Customer reassurance module)

 

Delivery policy (edit with Customer reassurance module)

 

Return policy (edit with Customer reassurance module)

Composition

Solution for parabulbar and / in the introduction.

1 ml. contains meldonium 100 mg.

Mechanism of action

Idrinol is a metabolic enhancer, an analogue of gamma-butyrobetaine. Inhibits gamma-butyrobetaine hydroxinase, inhibits Carnitine synthesis and transport of long-chain fatty acids through cell walls, prevents accumulation of activated forms of non-oxidized fatty acids - derivatives of acyl carnitine and acylcoenzyme A. in cells ATP; at the same time activates glycolysis, which proceeds without additional consumption of oxygen. As a result of reducing the concentration of carnitine, gamma-butyrobetaine with vasodilating properties is intensively synthesized. The mechanism of action determines the diversity of its pharmacological effects: increasing efficiency, reducing the symptoms of mental and physical overstrain, activation of tissue and humoral immunity, cardioprotective effect. In the case of acute ischemic myocardial damage, it slows down the formation of a necrotic zone, shortens the rehabilitation period. In heart failure, it increases myocardial contractility, increases exercise tolerance, and reduces the frequency of strokes. In acute and chronic ischemic disorders of cerebral circulation improves blood circulation in the ischemic focus, promotes the redistribution of blood in favor of the ischemic area. Effective with vascular and dystrophic pathology of the fundus. It has a tonic effect on the central nervous system, eliminates functional disorders of the nervous system in patients with chronic alcoholism with withdrawal syndrome.

Indications

For intravenous infusion: as part of a complex treatment of coronary artery disease (angina, myocardial infarction), chronic heart failure, dyshormonal cardiomyopathy; in the complex treatment of acute and chronic disorders of cerebral circulation (strokes and cerebrovascular insufficiency); reduced performance, physical stress (includingin athletes), the postoperative period to accelerate rehabilitation; abstinence syndrome in chronic alcoholism (in combination with a specific therapy of alcoholism).
For parabulbar injection: acute impairment of blood circulation in the retina, hemophthalmia and retinal hemorrhage of various etiologies, thrombosis of the central retinal vein and its branches, retinopathy of various etiologies (including diabetic and hypertensive) - only for parabulbar injection.

Contraindications

Increased intracranial pressure (including in violation of the venous outflow, intracranial tumors), pregnancy, lactation (breastfeeding), hypersensitivity to meldonium.

Side effects

Cardiovascular: rarely - tachycardia, changes in blood pressure.
From the side of the central nervous system: rarely - psychomotor agitation.
On the part of the digestive system: rarely - dyspeptic symptoms.
Allergic reactions: rarely - pruritus, redness, rash, swelling.

Interaction

When used together, meldonium enhances the effect of antianginal drugs, some antihypertensive drugs, and cardiac glycosides.
With simultaneous use of Meldonium with Nitroglycerin, Nifedipine, alpha-blockers, antihypertensive drugs and peripheral vasodilators, moderate tachycardia and hypotension may develop (caution is required for these combinations).

How to take, the course of administration and dosage

In connection with the possibility of an exciting effect, it is recommended to use it in the first half of the day. Dose set individually depending on the evidence and route of administration.
With the on / in the dose of 0.5-1 g 1 time / day., The duration of treatment depends on the evidence.
Parabulbar injected with 0.5 ml of solution for injection with a concentration of 500 mg / 5 ml for 10 days.

Overdosage

Symptoms: decrease in blood pressure, accompanied by headache, tachycardia, dizziness and general weakness.

Treatment: symptomatic

Special notes

Idrinol is not a first-line drug for acute coronary syndrome.

Influence on ability to drive motor transport and control mechanisms:

Data on the adverse effects of the drug Idrinol on the speed of psychomotor reactions is not available.

Storage conditions

At a temperature not higher than 25 ° C

On prescription

32 Items